NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Senti, since this 2016 car-t study is a very muddled case report, I’d like to start by asking you an even more radical question.

Is it possible “tumors” 6, 7 and 8 were not tumors? I don’t think a biopsy was done on them. Same question about “tumors” 9, 10, 11 and 12?

Here is why I think it can’t be ruled out.

Consider the later GBM egfrviii (mutation) and egfr wildtype (normal) trial (different car-t therapy than the case report you are analyzing)with three patients. There was a brief period when nodules came and went:

In the workup of cyclic fevers in Participants 2 and 3, development of transient pulmonary nodules and ground-glass opacities was observed on chest computed tomography. These findings were otherwise asymptomatic and had spontaneously and completely resolved on repeat imaging within 4 to 6 weeks. None of the participants received glucocorticoids during the initial post-treatment phase or for any therapy-related indication.

https://www.nejm.org/doi/full/10.1056/NEJMoa2314390

Do you see what I mean?

Next issue, when the trial states all tumors decreased 77 to 100%, how can this be for tumors one through three if they were already removed with no recurrence.

The case report contains the errors that you located, I’m just wondering if it was even more complex than that? If “tumors” 9 through 12 were recurrence tumors and not nodules, what was the outcome for the patient? Do we know? Was there any follow up?

Finally, can you explain when the before and after scans were taken in illustration 2d?